The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | ASPEN-06: evaluating evorpacept plus TRP in HER2+ advanced gastric cancer
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the Phase II/III ASPEN-06 trial (NCT05002127) of evorpacept in combination with paclitaxel, ramucirumab, and trastuzumab (Evo-TRP) in previously treated human epidermal growth factor receptor 2 (HER2)-positive gastric and gastroesophageal cancer. Evorpacept, a CD47-blocking agent, enhances antibody-mediated defence and phagocytosis, particularly with monoclonal antibodies like trastuzumab. In Phase II, Evo-TRP showed a higher objective response rate and favorable trends in progression-free survival. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
